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Abstract
Background: Network analysis has been performed on large-scale medical data, capturing the global topology of drugs,
targets, and disease relationships. A smaller-scale network is amenable to a more detailed and focused analysis of the
individual members and their interactions in a network, which can complement the global topological descriptions of a
network system. Analysis of these smaller networks can help address questions, i.e., what governs the pairing of the
different cancers and drugs, is it driven by molecular findings or other factors, such as death statistics.
Methodology/Principal Findings: We defined global and local lethality values representing death rates relative to other
cancers vs. within a cancer. We generated two cancer networks, one of cancer types that share Food and Drug
Administration (FDA) approved drugs (FDA cancer network), and another of cancer types that share clinical trials of FDA
approved drugs (clinical trial cancer network). Breast cancer is the only cancer type with significant weighted degree values
in both cancer networks. Lung cancer is significantly connected in the FDA cancer network, whereas ovarian cancer and
lymphoma are significantly connected in the clinical trial cancer network. Correlation and linear regression analyses showed
that global lethality impacts the drug approval and trial numbers, whereas, local lethality impacts the amount of drug
sharing in trials and approvals. However, this effect does not apply to pancreatic, liver, and esophagus cancers as the
sharing of drugs for these cancers is very low. We also collected mutation target information to generate cancer type
associations which were compared with the cancer type associations derived from the drug target information. The analysis
showed a weak overlap between the mutation and drug target based networks.
Conclusions/Significance: The clinical and FDA cancer networks are differentially connected, with only breast cancer
significantly connected in both networks. The networks of cancer-drug associations are moderately affected by the death
statistics. A strong overlap does not exist between the cancer-drug associations and the molecular information. Overall, this
analysis provides a systems level view of cancer drugs and suggests that death statistics (i.e. global vs. local lethality) have a
differential impact on the number of approvals, trials and drug sharing.
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Introduction
Cancer is a complex disease, with many subtypes, affecting
various tissues in diverse ways, thus giving rise to an abundance of
chemotherapies. Taken together, cancers are the second leading
cause of death in the United States [1]. The common features of
cancer include uncontrolled cell growth, reduction in apoptosis,and
loss of cell cycle regulation, while other features are more tissue
specific and thus differentiate them and their chemotherapies.
In a global network level analysis of different diseases, where the
vertices represented diseases and the edges represented connec-
tions between diseases that share common genetic background,
most diseases were less connected, while a limited number of
diseases, mostly cancers, were highly connected hubs [2].
Similarly, a network analysis of drugs, where the vertices
represented drugs and the edges represented connections between
drugs that share common protein targets, showed that drugs of
similar types clustered together, and most proteins were targeted
by a few drugs, whereas only a few proteins were targeted by many
drugs [3,4]. Cancers have fewer drugs that are used to treat them
as compared with the other diseases, and the targets for the cancer
drugs are at a shorter distance from the genes that are mutated in
the cancers [3]. Quantitative analysis of the drug targets showed
that proteins with at least 3 protein-protein interactions are more
likely to be targeted by drugs [5]. A recent network study
characterized the global map of many diseases, including cancers,
and their associations with drugs, where the vertices represented
diseases and the edges represented connections between diseases
that share common drugs [6]. This study was also concerned with
the global description of the network, and found that only a few
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connected; and most diseases, even those unrelated to each other,
are connected by a few links [6]. These studies constitute the
global topological analysis aspect of the emerging areas of network
medicine [7] and network pharmacology [8]. However, these
studies do not focus on the specific relationships between diseases
and drugs, to address questions, such as, how might these
relationships arise, or what factors may affect these relationships.
The field of medical sciences includes both basic molecular and
clinical research, the latter involves clinical trials. Clinical trials
apply biomedical protocols to humans that aim to intervene or
observe a disease, e.g., testing drugs on cancers (http://
clinicaltrials.gov). Clinical trials provide preliminary evidence of
the efficacy, risks and optimum usage of the drugs. Phase 1 and 2
clinical trials are performed on small groups of individuals to
evaluate their safety and efficiency. Phase 3 clinical trials are
performed on a large group of individuals, to evaluate their
efficiency, side effects and how they compare with approved drugs.
Phase 4 clinical trials are performed after the drug has been
approved for use, to obtain additional information. The United
States Food and Drug Administration (FDA) regulates the
approval and labeling of the drugs with regard to their safety,
efficacy, and security to humans (http://www.fda.gov). In addition
to the clinical drug trial and FDA approval data, death statistics,
such as the estimated cases and estimated deaths over the years are
available for the different cancer types [9]. Cancer is a large class
of disease with various types, each with its own specific approvals,
trials, death statistics, and molecular information, i.e., mutation
targets. These diverse data provide opportunities to perform an
integrative, systems level analysis of the cancers to reveal potential
relationships between the various types of cancer and the drugs
used to treat them and possible trends or factors that influence
these relationships.
Global network analyses have been previously applied to
describe the overall topology of disease and drug relationships,
i. e, very few diseases and drugs are highly connected, while most
members of these networks are less connected [2,3,4,6].Smaller
network systems, such as in this study, are amendable to a more
focused analysis of individual members of the network, whereas
larger networks are not, and hence are more amendable to
statistical topological analyses, such as degree distribution analysis
[10]. We propose that a drug approved or used in clinical trials for
treating several cancers may hint to a relationship between those
cancers. Similarly, a mutation involved in or a drug target used in
treating different cancers may suggest a relationship between these
cancers. System level analysis of these relationships could reveal
potential factors involved in the development of these complex
relationships that are not readily apparent from the data itself. In
contrast to the previous medical network analyses, the analysis of
smaller networks of cancer-drug and cancer-target associations
permits a more detailed evaluation of the specific relationships
between individual cancers. Through correlation and linear
regression analyses of the number of approvals and trials, and
weighted degree values, with the cancer lethality values, we
assessed whether the death statistics impact the formation of
associations between the cancers and drugs. Our analyses suggest
that global lethality has an affect on the number of FDA approved
and clinical trial cancer drugs. Comparative analysis of the cancer
networks based on the FDA approved drugs and clinical trial drugs
showed that some cancers are significantly and highly connected
in the clinical trial cancer network but not in the FDA cancer
network, and vice versa. Correlation and linear regression analyses
suggest that local and global lethality differentially impact the
sharing of FDA approved cancer drugs and the sharing of clinical
trial drugs. Further, a comparison of the mutation target-based
with the FDA drug target-based cancer networks suggests that the
molecular information about a cancer does not strongly influence
the cancer drug approvals.
Results and Discussion
FDA cancer drug approvals and clinical cancer drug trials
We collected the drugs approved through 2009 by the FDA
for 23 cancer types and the clinical trials completed by 2009 for
these same drugs (Dataset S1-S3). We compared these 81 drugs
for the 23 cancer types, and checked which drugs had i)
completed Phase 1 and 2 trials but were not listed under Phase 3
clinical trials and thus were not FDA approved, ii) completed
Phase 3 clinical trial but were not FDA approved, iii) was FDA
approved and in Phase 3 clinical trial (Table 1), and iv) was
FDA approved and was not in clinical trials. There are several
drugs for which Phase 3 clinical trial was completed but were
not FDA approved (item ii). For example, cisplatin was
approved for only testicular and bladder cancers, and has
undergone and completed Phase 3 clinical trials for many types
of cancer but has yet to be listed as approved by the FDA for
those cancers (Table 1). The clinical trial data is incomplete (see
Materials and Methods section for details). For example, there
are some drugs which were FDA approved but not listed under
any past clinical trials, completed or otherwise, which suggests
that the analysis of the clinical trials will not be comprehensive.
Leukemia, breast cancer, lung cancer, and lymphoma have the
highest number of drug approvals and the highest number of
clinical trials (Table 2, Figure S1). The percentage of clinical
trials or FDA approvals for the different cancers were calculated
as the number of clinical drug trials or FDA drug approvals for a
specific cancer type, divided by the total number of clinical drug
trials or FDA drug approvals for the 23 cancers analyzed in this
study. The clinical trial and FDA approval percentages are
similar for many of the cancers in this study (Figure 1). There
are a few notable exceptions, namely breast cancer and
myeloma, which have much higher percentages of FDA
approvals than of clinical trials.
Global and local lethality values for cancer types
Death and survival ratios have been predominantly used to
describe the values of global and local significance of cancer deaths
[9]. It is confusing to use these values since one uses death and the
other uses survival numbers to describe global and local death
statistics of a specific cancer. Therefore, we defined two different
death-based statistics, a global and a local lethality rate by using
the estimated death and new case numbers of each cancer (Table 2
and S1). The percentage of global lethality is calculated as the ratio
of estimated number of deaths for a cancer to the estimated
number of deaths for all cancers. The percentage of local lethality
is calculated as the ratio of estimated number of deaths to the
estimated number of cases for a particular cancer. The global
lethality provides a perspective of a particular cancer with respect
to the other cancers, whereas, the local lethality is specific to each
cancer type. A cancer with a high local lethality suggests that it has
a high number of deaths within its own incidences, while its global
lethality may or may not be high. For example, pancreatic cancer
is a locally lethal but not globally lethal cancer; it has a local
lethality value of 0.91 but a global lethality value of 0.06 (Table 2).
This is because most of the pancreatic cancer patients have low
survival rates, but comparatively there are fewer cases of
pancreatic cancer.
Clinical Cancer Networks
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PLoS ONE | www.plosone.org 4 April 2010 | Volume 5 | Issue 4 | e10031Table 2. FDA approvals, clinical trial, weighted degree values and death statistics of cancers in this study.
Cancer type
FDA drug
approval
number
FDA
specific
drug
approval
number
FDA
specific
drug
percentage
FDA
original
drug
approval
number
Clinical
drug trial
number
FDA cancer
network
weighted
degree
value
FDA
weighted
degree
p-value
Clinical trial
cancer
network
weighted
degree
value
Clinical
trial
weighted
degree p-
value
Global
lethality
ratio
Local
lethality
ratio
lung cancer 14 3 21.4% 1 121 1.32 0.029 7.58 0.066 0.286 0.753
colorectal cancer 8 4 50.0% 3 61 0.46 0.840 6.15 0.899 0.088 0.336
breast cancer 19 10 52.6% 2 97 1.17 0.003 6.81 0.037 0.072 0.222
pancreatic cancer 3 0 0.0% 1 35 0.5 0.898 6.96 0.576 0.061 0.910
prostate cancer 4 3 75.0% 0 48 0.41 0.937 4.32 0.998 0.051 0.154
leukemia 23 16 69.6% 0 170 0.65 0.157 5.16 0.656 0.038 0.490
lymphoma 16 9 56.3% 0 121 0.83 0.195 6.41 0.013 0.036 0.276
liver cancer 1 0 0.0% 0 19 0.33 0.899 6.57 0.714 0.033 0.862
endometrial cancer 1 0 0.0% 0 10 1.06 0.653 4.43 0.996 0.028 0.186
ovarian cancer 6 2 33.3% 2 71 1.16 0.488 7.42 0.018 0.027 0.717
esophagus cancer 1 0 0.0% 1 26 0.07 0.970 6.8 0.605 0.025 0.867
bladder cancer 2 1 50.0% 0 10 0.25 0.967 4.34 0.997 0.025 0.205
brain cancer 3 1 33.3% 1 62 0.89 0.748 6.57 0.606 0.023 0.599
kidney cancer 3 1 33.3% 1 30 0.5 0.899 7.22 0.221 0.023 0.239
skin cancer 4 1 25.0% 2 31 0.48 0.885 5.84 0.924 0.020 0.165
myeloma 8 3 37.5% 1 13 0.86 0.563 2.81 1.000 0.019 0.537
stomach cancer 4 0 0.0% 1 19 1.13 0.609 6.32 0.759 0.019 0.506
cervical cancer 1 0 0.0% 0 20 0.24 0.939 5.48 0.932 0.007 0.350
testicular cancer 3 1 33.3% 2 11 0.31 0.966 5.31 0.984 0.001 0.047
eye cancer 1 0 0.0% 0 2 0.78 0.691 1.58 1.000 0.000 0.100
head and neck cancer 3 0 0.0% 0 45 1.35 0.558 8.03 0.056 - -
mesothelioma 1 0 0.0% 0 40 0.07 0.984 3.23 1.000 - -
sarcoma 2 0 0.0% 1 7 1.21 0.636 7.39 0.259 - -
doi:10.1371/journal.pone.0010031.t002
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Figure 1. Cancer drug approval and clinical trial percentages. FDA cancer drug approval and clinical drug trial percentages for 23 cancers.
doi:10.1371/journal.pone.0010031.g001
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We hypothesize that there are factors, such as the lethality
values of a cancer, that may influence the number of clinical trials
and, in turn, FDA approvals. To quantitatively evaluate whether
lethality values are related to the number of FDA drug approvals
and clinical drug trials, Spearman correlation coefficients were
calculated between the global/local lethality measures and the
trial/approval numbers. The correlation analyses suggest that
global lethality is correlated, whereas local lethality is not
correlated, to both the clinical trial and FDA approval numbers
(Table 3). To further evaluate the impact of lethality values on the
FDA drug approvals and clinical drug trials, we performed a linear
regression analysis. Linear fit of the clinical trial numbers with
global lethality suggests a slight but albeit significant relationship
(r
2=0.25, p=0.03, Figure S2). This suggests the higher clinical
drug trial numbers could be explained, in part, by the higher
global lethality rates. Next, we considered whether the relation-
ships found by correlation and linear regression analyses are
affected by lung cancer, the most globally lethal cancer, and
pancreatic, esophagus, and liver cancers, the most locally lethal
cancers (see Table 2 and the Materials and Methods section). We
re-calculated the correlations by removing the globally or locally
lethal cancers. No significant change in the correlations resulted
upon removing lung cancer. However, a linear fit of the FDA
approval numbers with global lethality suggests a slight relation-
ship which is significant, when lung cancer is excluded (r
2=0.20,
p=0.05, Figure S2). The significance of the correlation and the
linear fit between local lethality with FDA approval and clinical
trial numbers increased upon removing the most locally lethal
cancers, pancreatic, liver and esophagus cancers (Figure S2,
Table 3). Local lethality has a significant correlation with clinical
trial drug numbers for the cancers other than the most locally
lethal ones. This suggests the number of FDA approvals and
clinical trials are much lower for pancreatic, liver and esophagus
cancers as compared to other cancers despite their very high local
lethality (Text S1). Although, the linear fit p-values of local
lethality with FDA approval numbers and clinical trial numbers
decreased, when pancreatic, liver and esophagus cancers are
excluded, they are not very significant (Figure S2). We also
analyzed whether the FDA approval numbers from previous years
correlated with the lethality values. The correlation of global
lethality with the FDA approval numbers has mostly been present
in previous years (Table S2). The correlation and linear regression
analyses suggest that global lethality has an impact on the drug
trial and approval numbers, for the cancers in this study.
Weighted cancer networks
The global relationships between drugs and diseases have been
analyzed topologically in large-scale networks of drugs and diseases
[2,3,4,6]. Complex relationships between the types of cancer and
drugs constitute a smaller network structure. Unlike the larger
networks, a smaller network system, as in this study, are amendableto
a more focused analysis of individual members of the network rather
than statistical topology-based parameters [10]. Weapplied this more
focused analysis, where individual members and interactions in the
networks were studied rather than their global structure, to elucidate
the drug therapy based relationships between various cancers and the
factors that may influence these relationships.
The collection of cancer-drug pairs make up a bipartite network,
which we transformed into a unipartite weighted network consisting of
only cancers. To construct a weighted network of cancers, an edge
between any two cancers was assigned, if there is at least one drug
which was approved by FDA to treat both types of cancers (Figure 2,
Dataset S1, Table S3). The weight of an edge was defined by the
Jaccard index, which is the fraction of drugs which were approved for
both cancers over all the drugs which were approved for each of the
two cancers, separately (see Materials and Methods). Weighted degree
values were not significantly correlated with the number of FDA
approvals (Pearson correlation coefficient of 0.34, p=0.11), suggesting
that the number of drugs approved for a cancer does not implicate the
number of drugs shared with other cancers. We, further, assessed the
significance of the weighted degree values by a permutation test, while
keeping the number of drugs per cancer type constant, and found the
degree of drug sharing is not significant for most of the cancers
(Table 2), except for lung and breast cancer These two cancers have
significant weighted degree values in the FDA cancer network. Lung
cancer shares FDA drugs with many other cancers (Figure 2, Table
S3). Leukemia, the cancer type with the highest number of FDA
Table 3. Correlation values of weighted degree, approval number values and of FDA specific drug percentage with global and
local lethality values.
Global lethality Local lethality
All cancer types
All cancer types
except globally
lethal cancers
(lung cancer) All cancer types
All cancer types except
locally lethal cancers
(pancreatic, esophagus
and liver cancers)
FDA approval number 0.50 0.44 0.05 0.42 Spearman statistic
0.03 0.06 0.85 0.09 Spearman p-value
Clinical trial number 0.67 0.63 0.34 0.53 Spearman statistic
0.00 0.00 0.15 0.03 Spearman p-value
FDA cancer network weighted degree 0.25 0.12 0.14 0.53 Spearman statistic
0.29 0.62 0.57 0.03 Spearman p-value
Clinical trial cancer network weighted
degree
0.42 0.33 0.61 0.55 Spearman statistic
0.06 0.17 0.00 0.03 Spearman p-value
FDA specific drug percentage 0.35 0.44 20.32 20.05 Spearman statistic
0.13 0.06 0.17 0.85 Spearman p-value
doi:10.1371/journal.pone.0010031.t003
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FDA cancer network (Table 2). This is because leukemia does not
share many of its FDA approved drugs with other cancers. Indeed, as
discussed later, leukemia has many specific drugs (see section ‘‘Drugs
specific to particular cancer types’’). We also analyzed the FDA cancer
network over time, by including the cancer drug approvals for the
different years (Figure S3-S4, Text S1). Based on the average weight
values of the networks, there is no major change over the years.
Weighted degree values for most of the cancers also are not significant
in the previous years’ networks. However the breast cancer weighted
degree value has been significant since 2000 and the lung cancer
degree value has become significant recently (Table S4). Weighted
degree values of lung and breast cancer have been increasing and
significantly higher than the other cancers since 2006 (Figure 3). In
recent years, FDA approved drugs for these cancers (the 1
st and 3
rd
most globally lethal) have a high overlap with other cancers.
A weighted clinical trial-based cancer network was also constructed
(herein denoted as clinical trial cancer network), where two cancers
were connected if there is at least one FDA approved drug (approved
for at least a cancer) in the clinical trial data for both cancers (Dataset
S3, Table S3). The clinical trial cancer network is almost a complete
network, because of the large number of drugs that were used in
clinical trials for the different cancers, thereby connecting many of the
cancers, albeit not all, to each other (Figure S5). The significance of the
weighted degree values was evaluated by a permutation test, with the
number of drug trials kept constant. Breast cancer, ovarian cancer, and
lymphoma have significant weighted degree values in the clinical trial
cancer network (Table 2). Also, the weighted degree values of lung
cancer and head and neck cancer are close to being significant. This
indicates that these cancers shares clinical trial drugs, significantly, with
other cancers. In addition, we calculated the difference in the edge
weights between the FDA and clinical trial cancer networks for each
cancer pair, and identified that most pairs are strongly connected in the
clinical trial but not in the FDA cancer network (Table S3). For
example, stomach and esophagus cancers are strongly connected in the
clinical trial cancer network (Table 4). There are many drugs used in
clinical trials for both types of cancers, i.e., capecitabine, cisplatin,
doxorubicin, erlotinib, fluorouracil, irinotecan, ixabepilone, leucovorin,
Figure 2. FDA cancer network. Vertices represent cancers whereas
edges represent the drug approval-based interaction between them.
The network includes only the cancers which have at least one
interaction with other cancers.
doi:10.1371/journal.pone.0010031.g002
Figure 3. Weighted degree values breast and lung cancers in the previous years. Weighted degree values of breast cancer, lung cancer,
and the remaining cancers in the FDA cancer networks from 2000 to 2008. Average and the standard deviation of the weighted degree values are
shown. Wilcoxon test was performed for greater values of lung and breast cancer than the other cancers. The networks with p-values lower than 0.05
are indicated by asterisk (*).
doi:10.1371/journal.pone.0010031.g003
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these two cancers. However, they are not connected in the FDA cancer
network, i.e. no drug is approved by the FDA for both stomach and
esophagus cancers; porfimer was approved for esophagus cancer while
docetaxel, fluorouracil, imatinib, and sunitinib were approved for
stomach cancer. There are a few pairs of cancers which are more
highly connected in the FDA cancer network than in the clinical trial
cancer network (Table 4 and S3). For example, sarcoma and endo-
metrial cancer pair has a weight of 0.5; they share methotrexate which
is the only drug approved for endometrial cancer and one of the two
drugs approved for sarcoma. On the other hand, there are many drugs
in the clinical trial data for each of these two cancers which are not
shared between them, such as altretamine, capecitabine, etoposide, etc
(Dataset S3). Weighted networks of cancers based on FDA approvals
and clinical trials show different characteristics. Breast cancer is the
only cancer with a significant degree value in both the FDA and the
clinical trial cancer networks. While lung cancer is more significantly
connected only in the FDA cancer network, ovarian cancer and
lymphoma are more significantly connected in the clinical trial cancer
network (Table 2). This suggests that ovarian cancer and lymphoma
have a high overlap of drugs in clinical trials but not in FDA approvals.
Effect of lethality on the cancer networks
Given that the lethality of a cancer impacts the number of
drug trials and approvals, it raises the question of whether it
could also influence the FDA and clinical trial cancer networks
and if there could be differences in their influence on these two
networks. We analyzed the correlation and the linear fit
between the weighted degree values of the FDA/clinical trial
cancer networks and the global/local lethality values. The
weighted degree values for the clinical trial cancer network are
correlated with local lethality (Table 3). Linear regression
between the weighted degree values and the lethality values
shows a partial but significant relationship between local
lethality and clinical trial network weighted degree (r
2=0.26,
p=0.02, Figure S6). This suggests that sharing of drugs in
clinical trials is impacted positively by local lethality values.
The weighted degree values of the FDA cancer network are not
significantly correlated with the global and local lethality values
(Table 3). Next, we analyzed the effect of the most globally lethal
(lung cancer) and the most locally lethal cancers (pancreatic,
esophagus and liver cancers) on these correlations and linear fits.
Weighted degree values of the FDA cancer network are
significantly correlated with local lethality after removing pancre-
atic, liver, and esophagus cancers (Table 3, Figure 4A–4B). Linear
fit analysis suggests that the weighted degree of a cancer in the
FDA cancer network tend to be high if its local lethality value is
high. However, the most locally lethal cancers (pancreatic,
esophagus and liver cancers) are excluded from this effect since
they have lower than expected weighted degree values, as
compared to the other cancers (Text S1). We also analyzed if
the FDA cancer networks from previous years correlated with the
lethality values. Global lethality and local lethality do not have a
significant correlation in the older FDA cancer networks.
However, more recently (2007) the cancer network has become
correlated with local lethality, with the exclusion of pancreatic,
liver, and esophagus cancers (Table S2).
Analysis of the weighted degree values of the cancer networks
provides information on the level of drug sharing between cancers.
We showed that local lethality has an effect on the clinical cancer
drug trial sharing as well as FDA approved drug sharing, the latter
appears to be a recent trend. However, the most locally lethal
cancers, pancreatic, liver, and esophagus cancers, are biased
towards having lower levels of sharing of FDA approved drug. For
the most local lethality cancers, although sharing of drugs in
clinical trials correlates positively with local lethality values, the
sharing of the approved drugs does not correlate with local
lethality values.
Table 4. Cancer pairs with a weight difference of at least 0.5 or lower than 0.
Cancer type 1 Cancer type 2
Clinical trial cancer
network weight
FDA cancer network
weight Difference
stomach cancer esophagus cancer 0.71 0.00 0.71
head and neck cancer kidney cancer 0.56 0.00 0.56
kidney cancer lung cancer 0.54 0.00 0.54
ovarian cancer head and neck cancer 0.54 0.00 0.54
leukemia lymphoma 0.68 0.15 0.53
ovarian cancer breast cancer 0.61 0.09 0.53
cervical cancer esophagus cancer 0.50 0.00 0.50
head and neck cancer brain cancer 0.50 0.00 0.50
head and neck cancer liver cancer 0.50 0.00 0.50
stomach cancer cervical cancer 0.50 0.00 0.50
brain cancer myeloma 0.17 0.22 20.05
ovarian cancer myeloma 0.10 0.17 20.06
head and neck cancer endometrial cancer 0.25 0.33 20.08
ovarian cancer eye cancer 0.06 0.17 20.11
eye cancer myeloma 0.00 0.13 20.13
brain cancer eye cancer 0.12 0.33 20.21
sarcoma endometrial cancer 0.22 0.50 20.28
doi:10.1371/journal.pone.0010031.t004
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cancer types
Network analysis captured the overlap in cancer drug use,
however, only 26 of the total 81 cancer drugs were approved for
more than one cancer type. Therefore we analyzed the
distribution of the remaining 55 drugs which were approved
specifically for only one type of cancer. A drug which was
approved by the FDA solely for a single cancer is denoted as a
‘‘specific’’ FDA drug. We calculated the specific drug percentage
for a cancer as the ratio of the number of specific drugs to the total
number of drugs approved by the FDA. Prostate cancer, leukemia,
breast cancer, and lymphoma have the highest specific drug
percentage approved by the FDA (Figure 5). The most locally
lethal cancers, pancreatic, liver, and esophagus cancers, have no
specific drugs (Table 2). Globally lethal cancer, i.e., lung cancer,
has a low percentage of FDA specific drugs (Table 2, Figure 5).
The number of specific drugs in clinical trials is very low, therefore
it was not analyzed further (Table S5). We also analyzed the
possible effect of lethality on the percentage of FDA specific drug
approvals and showed that there is no significant effect based on
correlation and linear regression analyses (Table 3 and Figure S7).
There is also a notable difference among the non-specific (shared)
drugs, such that some of the drugs were first approved for a cancer
type and then approved for other cancer types, while other drugs
might be approved for more than one type of cancer at the same
time. We defined whether a drug was ‘‘originally approved’’ by the
FDA for a specific cancer type and then approved for other cancers
after at least a year. Colorectal cancer has the highest number of
‘‘originally approved’’ FDA drugs (Table 2). There is only one
originally approved FDA drug, erlotinib for lung cancer (Table 2,
Dataset S1). Manymore drugs were approved forother cancers that
were subsequently approved for lung cancer (11 drugs) than were
‘‘originally approved’’ for lung cancer (only one).
Comparison of clinical and molecular target based cancer
networks
In addition to the death statistics, we asked whether molecular
information impacted the cancer-drug associations. To compare
Figure 4. FDA cancer network weighted degree vs. local lethality ratio. FDA cancer network weighted degree values are plotted against
local lethality ratio for (A) 23 cancers (r
2=0.01, p=0.78), (B) the cancers except pancreatic, liver and esophagus cancers (r
2=0.35, p=0.01). Lung
cancer is shown as an open triangle and pancreatic, liver, esophagus cancers are shown as open circles.
doi:10.1371/journal.pone.0010031.g004
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relationships for the different cancer types, we constructed
weighted molecular and clinical cancer networks (Figure S8)
based on mutation targets and FDA approved drug targets
(Dataset S4–S6, Table S6–S7), respectively. The edges between
two cancers in the mutation target based network was assigned if
there is at least one mutation target associated with both cancers
and the edges between two cancers in the drug target based
network was assigned if there is at least one drug target associated
with both cancers. The weights of the edges were defined by the
Jaccard index (Table S6–S7). To compare the mutation target-
based and the drug target-based cancer networks, we included
only the cancers that have both mutation and drug target data. We
calculated the weighted degree values for the different cancers and
evaluated the significance of the weighted degrees with permuta-
tion test, keeping the distribution of target numbers for each
cancer constant (Table 5). The weighted degree values of the
mutation and drug-target based cancer networks are not strongly
correlated (Pearson correlation coefficient of 0.37, p=0.11). Lung
and breast cancers have significant and high weighted degree
values in the drug target-based network but not in the mutation
target-based network (Table 5). On the other hand, colorectal,
ovarian and brain cancers have significant weighted degree values
in the mutation target-based network but not in the drug-target
based network (Table 5). Leukemia is the only cancer which has
significant weighted degree values in both networks.
The overlap between the two networks is very low (Figure S8)
and for the overlapping edges, we calculated the difference in
mutation and drug target weight values (Table 6 and S8).
Colorectal-ovarian, ovarian-endometrial, and endometrial-colo-
rectal cancer pairs have higher mutation target-based weights than
drug target-based weight values (Table 6). These cancers are
connected to each other in the mutation target-based network
through the following mutations: PMS1, PMS2, MLH1, MSH2,
and MSH6, which are proteins responsible for DNA mismatch
repair. On the other hand, all three cancers share no drug targets.
Since they share many mutation targets, this suggests that they
could have similar molecular mechanisms, and thus raises the
question if they should share drug targets. On the other hand,
kidney and liver cancers, which do not share any mutation targets,
have a high overlap of drug targets (Table S8). They share drug
targets such as FLT4, PDGFRB, BRAF, etc. (Dataset S5). There
could be mutation targets common to these cancers which may not
have been identified or is absent in the current dataset.
Alternatively, they could share molecular mechanisms without
sharing mutation targets, i.e., similar pathways may be affected in
both cancers despite different mutated genes.
We also evaluated the cancers that are associated with proteins
that are both mutation and drug targets (Table 7). Only leukemia,
lung, and breast cancers have mutation targets that are also drug
targets. For example, ERBB2, a member of EGFR family, has
long been known as a mutation target for breast cancer [11].
Lapatinib, letrozole, and trastuzumab are drugs that target
ERBB2 in our data (Dataset S4) and all have been used in clinical
drug trials for only breast cancer and approved by the FDA for
only breast cancer (Dataset S1 and S3). Furthermore, ERBB1, a
member of the EGFR family, is known as a mutation target for
lung cancer [12]. There are several drugs which target ERBB1,
such as cetuximab, erlotinib, gefitinib, lapatinib, panitumumab,
and trastuzumab (Dataset S4), among which, only erlotinib and
gefitinib are approved only for lung cancer (Dataset S1). The
remaining drugs have not completed Phase 3 clinical trials.
Cetuximab, and trastuzumab have completed Phase 1 and 2 trials,
whereas clinical trials using lapatinib and panitumumab for lung
cancer have not yet completed Phase 1 and 2 trials (Table 1).
Overall, very few mutations have been approved as targets for
cancer therapy.
Comparison of mutation and drug-target based cancer networks
indicate that the overlap is very low. Various cancers have strong
associations in one but not in the other network. For instance, lung
Figure 5. FDA specific drug percentages. FDA and clinical trial specific drug percentages for the cancers except cervical, endometrial,
esophagus, liver, pancreatic, eye, sarcoma, mesothelioma, and stomach cancers, which do not have specific drugs.
doi:10.1371/journal.pone.0010031.g005
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but not mutation-target based associations. Similarly there are
pairs of cancers, such as the pair of colorectal and endometrial
cancers, with relatively high weights in the mutation-target based
network but not in the drug-target based network. This analysis
suggests that the influence of molecular information on the cancer-
associations is not strong, and there are very few proteins which
are both mutation-targets and drug-targets.
Conclusion
In this study, we present a systems level view of the cancer
drugs. Comparing clinical trial and FDA approval based cancer
networks, we showed that only breast cancer is significantly
connected in both networks. Lung cancer is significantly
connected in the FDA cancer network, whereas ovarian cancer
and lymphoma are significantly connected in the clinical trial
cancer network. This suggests that lung cancer has a high degree
of sharing of FDA approved drugs with the other cancers. Indeed,
it has the highest number of FDA approved drugs which are
shared with other cancers. In contrast, ovarian cancer and
lymphoma have a high degree of drug sharing in clinical trials
but not in FDA approvals.
We also assessed whether death statistics and molecular
information are related to the cancer-drug associations. We
showed that the cancer-drug associations are differentially
impacted by the type of lethality. Global lethality appears to have
an affect on the number of FDA approved drugs and clinical drug
trials, but not on the FDA approval and clinical trial-based drug
sharing, as determined by the cancer network weighted degree
values. On the other hand, local lethality has an affect on the FDA
approval and clinical trial-based drug sharing, but not on the
number of FDA approved drugs and clinical drug trials. The effect
of local lethality on the sharing of FDA approved drugs is not
present or captured by the most locally lethal cancers, pancreatic,
liver and esophagus cancers. These cancers are biased towards
having very low overlap of FDA approved drugs with other
cancers. For example, there is only one drug approved for liver
cancer, Sorafenib, which is shared with lung cancer; however
there are 13 more FDA approved drugs for lung cancer, which are
not approved for liver cancer, leading to the lower weight for liver
cancer (Dataset S1, Table S3). Although sharing of drugs in
clinical trials correlates positively with local lethality values,
however, it does not translate to increase sharing of the approved
drugs for the most locally lethal cancers. There could be a number
of reasons for this; the drugs in clinical trial are not being approved
for the most locally lethal cancers or they have not been approved
yet. For example, liver cancer and lung cancer share 13 drugs out
of total 32 drugs used in clinical trials for these cancers (Dataset
S3). 5 of these 15 common/overlapping clinical trial drugs are
approved for lung cancer by FDA but they are still in clinical trials
for liver cancer. Therefore they have a higher connection weight
in the clinical trial cancer network than the FDA cancer network
(Table S3). These findings support network-based analysis and
their ability to reveal relevant information distinct from the raw
data. It is not surprising that clinical decisions may be impacted by
death statistics. However, it is interesting that different types of
death statistics (global lethality vs. local lethality) show different
results. It should be kept in mind that this study does not capture
all aspects of the clinical drug data. For example, this analysis does
not account for the differential efficiencies of the various drugs
used in treating a particular cancer, which could have an impact
on why some cancers have few while others may have many more
Table 5. Weighted degree values of drug target and mutation target based networks.
Drug target based
network weighted
degree value
Drug target based
network weighted
degree p-value
Mutation target based
network weighted
degree value
Mutation target based
network weighted
degree p-value
leukemia 2.28 0.000 0.25 0.003
lung cancer 3.35 0.000 1.12 0.210
breast cancer 3.29 0.001 1.08 0.160
colorectal cancer 2.75 0.290 1.57 0.000
ovarian cancer 2.53 0.634 1.43 0.011
brain cancer 1.66 0.674 0.9 0.016
sarcoma 1.76 0.961 0.42 0.509
pancreatic cancer 0.62 1.000 0.82 0.706
endometrial cancer 0.66 0.996 0.78 0.732
eye cancer 1.79 0.309 0.17 0.880
stomach cancer 2.12 0.774 0.53 0.909
lymphoma 2.17 0.287 0.19 0.952
testicular cancer 1.83 0.817 0.33 0.980
skin cancer 2.22 0.808 0.35 0.981
bladder cancer 2.32 0.330 0.14 0.998
head and neck cancer 2.75 0.275 0.06 1.000
kidney cancer 1.38 0.996 0.13 1.000
liver cancer 1 0.999 0.26 1.000
myeloma 1.24 0.999 0.16 1.000
prostate cancer 0.88 1.000 0.19 1.000
doi:10.1371/journal.pone.0010031.t005
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limited to those which have already been approved by the FDA for
at least one cancer type and therefore do not include all cancer
drugs currently in clinical trial.
Currently, most cancer drugs are designed to target the general
mechanisms of cell division, which may not directly address the
specific molecular mechanisms that drive the development of the
type of cancer it aims to treat. We compared mutation and drug
Table 6. Mutation target- and drug target-based weight values of cancer pairs which have a positive difference between the drug
and mutation target-based values.
Cancer type 1 Cancer type 2
Difference of mutation target from
drug target based weight
colorectal cancer endometrial cancer 0.26
colorectal cancer ovarian cancer 0.24
endometrial cancer ovarian cancer 0.15
brain cancer colorectal cancer 0.14
ovarian cancer pancreatic cancer 0.14
colorectal cancer liver cancer 0.1
brain cancer sarcoma 0.09
brain cancer endometrial cancer 0.08
breast cancer stomach cancer 0.08
endometrial cancer stomach cancer 0.08
liver cancer pancreatic cancer 0.08
pancreatic cancer testicular cancer 0.08
brain cancer lung cancer 0.07
colorectal cancer pancreatic cancer 0.06
head and neck cancer kidney cancer 0.06
liver cancer ovarian cancer 0.06
brain cancer prostate cancer 0.05
endometrial cancer prostate cancer 0.05
eye cancer lung cancer 0.05
lung cancer stomach cancer 0.05
brain cancer breast cancer 0.03
brain cancer liver cancer 0.03
brain cancer pancreatic cancer 0.03
brain cancer stomach cancer 0.03
breast cancer eye cancer 0.03
breast cancer kidney cancer 0.03
colorectal cancer sarcoma 0.03
pancreatic cancer skin cancer 0.03
bladder cancer sarcoma 0.02
brain cancer kidney cancer 0.02
breast cancer sarcoma 0.02
eye cancer sarcoma 0.02
prostate cancer sarcoma 0.01
doi:10.1371/journal.pone.0010031.t006
Table 7. Cancers with at least one common mutation and drug target.
Cancer type Common mutation and drug target name and Entrez Gene ID
lung cancer ERBB1(1956)
breast cancer ERBB2(2064)
leukemia FCGR2B(2213), ABL1(25), PDGFRB(5159), KIT(3815), ABL2(27), LCK(3932), BCL2(596)
doi:10.1371/journal.pone.0010031.t007
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differences and noted that some cancer types share mutation
targets but not drug targets while others share drug targets but not
mutation targets, thereby hinting at the possibility that new drug
targets or mutation targets could be identified for these cancers.
Nevertheless, there are many other factors to consider when
evaluating the data. Although two cancer types may not have the
same mutation targets, they may have the same genes that are
differentially expressed, which could suggest the involvement of
similar molecular mechanisms. Given that cancer treatment
includes surgery, radiotherapy in addition to chemotherapy (http://
www.cancer.gov/cancertopics/treatment/types-of-treatment) thus, this
study provides a systems level analysis of the trends of one aspect of
clinical cancer research, namely from the perspective of the drugs that
are FDA approved or undergoing clinical trials.
In closing, we demonstrated a systems level view of the drugs
that have been approved and how they have been shared
between cancer types. Thus we envision that this study could be
informative to medical researchers from both the basic and
clinical sciences alike. The trends revealed in this study could be
monitored in the following years for any changes and these
analyses could be used to guide more in-depth analysis of
potential targets that could be involved in future clinical cancer
drug trials and approvals. For example, one could followed
whether the FDA approved drug sharing continues to be
significant for breast and lung cancers which appears to be
recent trends, beginning in the 2000s, and whether the overlap
between the molecular target based and the drug target based
cancer networks increases.
Materials and Methods
Drug-cancer pairs
We obtained lists of cancer drugs from the National Cancer Institute
Drug Information Summaries (http://www.cancer.gov/cancertopics/
druginfo/alphalist), and the FDA Center for Drug Evaluation and
Research (http://www.fda.gov/Drugs/default.htm). We used the
indication information by 2009 from the drug labels from the
Drugs@FDA, url: database (http://www.accessdata.fda.gov/scripts/
cder/drugsatfda/index.cfm?fuseaction=Search.Search_Drug_Name)
togeneratealistofdrug-cancerassociations(DatasetS1)thatincluded23
types of cancer. We renamed some cancers, for example, Kaposi’s
sarcoma is listed under skin cancer, glioma is listed under brain cancer,
and different types of leukemia and lymphoma are listed more generally
as leukemia and lymphoma, respectively. The time information tag of
the FDA approved label files is also used. Drugs discontinued in the
marketwereexcluded.Weobtainedclinicaltrialinformationforalldrug
trials completed by 2009 from the Clinical Trials database (http://
clinicaltrials.gov)(DatasetS2)andcollectedtheclinicaltrialsforthedrugs
and the cancer types that are in the list of FDA data (Dataset S3). We
differentiatedbetweenPhaseKandPhase3trialssincethePhaseKare
initial trials on small groups of patients, whereas Phase 3 trials are
performed on large groups of patients. We excluded Phase 4 trials since
they are post-approval. We did not include neoplasms in our analysis.
NamesofdrugsandcancershavebeenorganizedaccordingtotheFDA
data. In addition, we only collected the trials which were listed as drug
trials. These limitations could lead to loss of information, such that we
have FDA approval information for some drugs without completed
clinical trial information (Table 1). We observed that these limitations
could affect the clinical trial information prior to 2000s, namely, there
could be cases in which there is an approval of a drug earlier than the
trial dates. Therefore, we did not perform a time analysis of the clinical
trials.
Cancer death and survival statistics
The cancer statistics for 2001–2008 of the estimated number of
new cases and the estimated number of deaths for the different
types of cancers were obtained from the American Cancer Society
[9]. We defined two kinds of lethality values. Global lethality is
defined as the ratio of deaths of a particular cancer over all
cancers. Local lethality is defined as the ratio of deaths of a
particular cancer over the cases of that particular cancer. For
breast, ovarian, cervical cancers only the female population values
were considered. Likewise, for prostate and testicular cancers only
the male population values were used. For the other cancer types,
both the male and female population values were included (Table
S1). Lung cancer has the highest global lethality value, whereas
pancreatic cancer has the highest local lethality value. To
determine which other cancers are similar to lung and pancreatic
cancers with respect to their global and local lethality values, we
performed hierarchical clustering, based on Euclidean distance of
lethality values with single linkage. Lung cancer clustered by itself,
and pancreatic, liver and esophagus cancers clustered together
(Figure S9). Therefore only lung cancer is considered globally
lethal cancer, whereas pancreatic, liver and esophagus cancers are
considered locally lethal cancers.
Network construction
We constructed weighted clinical networks of cancer types, FDA
cancer network and clinical trial cancer network, from the drug-
cancer pairs (Dataset S1 and S3). In the clinical cancer networks
an edge was defined between two cancer types when there is at
least one drug which was approved or used in clinical trials for
both types of cancer (Table S3). The weight of the edge was
defined by the Jaccard index, which is the fraction of common
drugs for both cancer types over all the drugs for each of the
cancer types. For example, there is only one drug which was
approved for both pancreatic and stomach cancers, fluorouracil,
whereas there are 2 more drugs, erlotinib and gemcitabine, which
were approved for pancreatic cancer but not for stomach cancer,
and there are 3 more drugs, docetaxel, imatinib, and sunitinib,
which were approved for stomach cancer but not for pancreatic
cancer (Dataset S1). Therefore the weight of the edge between
these two cancers is 1/(1+2+3)=0.17 (Table S3). The resulting
FDA drug approval-based cancer network (herein denoted as FDA
cancer network) contains 23 types of cancer (vertices or nodes)
with 70 interactions (edges). We defined the weighted degree value
for a cancer as the sum of the weights of the edges for that cancer.
For example, pancreatic cancer shares drugs with stomach, lung,
colorectal and breast cancers, therefore its weighted degree is the
sum of the weights of the edges with these cancers, which is
0.17+0.13+0.1+0.1=0.5 (Table 1 and S3). This parameter
provides an account of the allocation of drugs for a particular
cancer and its neighbors in the network. If more drugs, which are
approved for other cancers, are approved for pancreatic cancer
(regardless of whether the drug is shared with stomach, lung,
colorectal and breast cancers or other cancers) in the future, its
weighted degree value will increase. Its weighted degree value will
decrease if more drugs are approved for stomach, lung, colorectal
and breast cancers but not for pancreatic cancer.
Similarly, we also constructed molecular target and clinical
target-based cancer networks (Table S6–S7), using mutation target
data from the Cancer Gene Census database (http://www.sanger.
ac.uk/genetics/CGP/Census/) [13] and FDA approved drug
target data from the DrugBank database (http://www.drugbank.
ca) (Dataset S4), respectively. Mutation target data from the
Cancer Gene Census database used was updated in January 2009
and includes mutation targets which have been implicated in the
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curation and thus captures information on the molecular
mechanisms that clinical researchers should have information
on. Cytoscape version 2.4 was used to visualize the networks [14].
Statistical analysis
The significance of the weighted degree values in the cancer
networks was analyzed by permutation tests. The distribution of
the number of drugs or drug and mutation targets was kept
constant while the cancer-drug or cancer-target associations were
randomized, respectively. The p-value for the weighted degree of a
cancer type is calculated as the fraction of the randomly generated
networks with a weighted degree value for a particular cancer
which is equal to or greater than the actual weighted degree value
of that particular cancer (Table 2 and 5). Conventional cutoff of
0.05 was used as a significance threshold. No multiple test
correction has been applied to the p-values. Therefore, given the
number of statistical tests performed, some of the associations
reported, particularly borderline significant, could be spurious. In
the FDA cancer network, Wilcoxon test is used to determine if the
weighted degree values of breast and lung cancer are higher than
the rest of the cancers in the network.
Shapiro-Wilk test suggests that some of the datasets used in this
study are not normally distributed (see Text S1). Therefore, we
used Spearman correlation coefficient values for the analysis of the
relationships between lethality values and the clinical trial and
approval numbers, and the network weight values (Table 3). The
significance of the correlations was determined by a permutation
based algorithm [15]. We also analyzed the dependence of the
clinical trials, FDA approval, weighted degree and specific drug
percentage values to the lethality values by linear regression
(Figure S2, S6 and S7). The significance of the linear regression
was determined by the p-values of the F-test. Multiple r
2 values of
the linear fit are also provided. Linear fit parameters and their
95% confidence intervals are in the supplementary figure legends.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0010031.s001 (0.02 MB
DOC)
Figure S1 FDA drug approval and clinical drug trial numbers.
Number of FDA approvals (A) clinical trials (B) for 23 cancers in
this study.
Found at: doi:10.1371/journal.pone.0010031.s002 (0.04 MB
PDF)
Figure S2 FDA approval and clinical trial numbers vs. lethality
values. FDA approval number values are plotted against global
lethality ratio for (A) 20 cancers (r2=0.17, p=0.07, equation:
y=44.70x +4.28, 95% confidence intervals: (23.59, 92.99), (0.70,
7.86)), (B) the cancers except lung cancer (r2=0.20, p=0.05,
equation: y=127.67x +1.84, 95% confidence intervals: (21.60,
256.94), (23.14, 6.81)). FDA approval number values are plotted
against local lethality ratio for (C) 20 cancers (r2=0.00, p=0.99,
equation: y=20.04x +6.27, 95% confidence intervals: (211.71,
11.62), (0.38, 12.16)), (D) the cancers except pancreatic, liver and
esophagus cancers (r2=0.09, p=0.23, equation: y=9.66x +3.72,
95% confidence intervals: (26.84, 26.16), (22.96, 10.40)). Clinical
trial number values are plotted against global lethality ratio for (E)
20 cancers (r2=0.25, p=0.03, equation: y=374.90x +32.31, 95%
confidence intervals: (52.26, 697.54), (8.39, 56.24)), (F) the cancers
except lung cancer (r2=0.21, p=0.05, equation: y=877.21x +17.53,
95% confidence intervals: (3.98, 1750.45), (216.06, 51.13)). Clinical
trial number values are plotted against local lethality ratio for (G) 20
cancers (r2=0.03, p=0.49, equation: y=27.36x +37.19, 95%
confidence intervals: (253.25, 107.97), (23.53, 77.91)), (H) the cancers
except pancreatic, liver and esophagus cancers (r2=0.20, p=0.07,
equation: y=101.04x +17.80, 95% confidence intervals: (210.51,
212.60), (227.32, 62.93)). Lung cancer is shown as an open triangle
and pancreatic, liver, esophagus cancers are shown as open circles.
Found at: doi:10.1371/journal.pone.0010031.s003 (0.04 MB
PDF)
Figure S3 FDA cancer networks of previous years. FDA cancer
network of (A) 1949, (B) 1986, (C) 1991, (D) 1993, (E) 1997, (F)
1998, (G) 2000, (H) 2003, (I) 2004, (J) 2005, (K) 2006.
Found at: doi:10.1371/journal.pone.0010031.s004 (0.87 MB
PDF)
Figure S4 Time dependent characteristics of the FDA approvals
and FDA cancer network. (A) Number of cancers in the network
from 1980–2008, (B) Number of FDA approvals from 1980–2008,
(C) Average weight of the network from 1980–2008, (D) Number
of components of the network from 1980–2008.
Found at: doi:10.1371/journal.pone.0010031.s005 (0.04 MB
PDF)
Figure S5 Clinical trial cancer network.
Found at: doi:10.1371/journal.pone.0010031.s006 (0.09 MB
PDF)
Figure S6 FDA and clinical trial cancer network weight values
vs. lethality values. FDA cancer network weight values are plotted
against global lethality ratio for (A) 20 cancers (r2=0.18, p=0.07,
equation: y=2.53x +0.56, 95% confidence intervals: (20.18,
5.23), (0.36, 0.76)), (B) the cancers except lung cancer (r2=0.01,
p=0.69, equation: y=1.47x +0.59, 95% confidence intervals:
(26.18, 9.12), (0.30, 0.88)). FDA cancer network weight values are
plotted against local lethality ratio for (C) 20 cancers (r2=0.01,
p=0.78, equation: y=0.09x +0.63, 95% confidence intervals:
(20.56, 0.74), (0.30, 0.96)), (D) the cancers except pancreatic, liver
and esophagus cancers (r2=0.35, p=0.01, equation: y=0.96x +
0.40, 95% confidenceintervals:(0.23, 1.69), (0.11, 0.70)).Clinical trial
cancer network weight values are plotted against global lethality ratio
for (E) 20 cancers (r2=0.15, p=0.09, equation: y=10.02x +5.26,
95% confidence intervals: (21.66, 21.70), (4.40, 6.13)), (F) 20 cancers
except lung cancer (r2=0.14, p=0.12, equation: y=24.85x +4.83,
95% confidence intervals: (27.28, 56.98), (3.59, 6.06)). Clinical trial
cancer network weight values are plotted against local lethality ratio
for (G) 20 cancers (r2=0.26, p=0.02, equation: y=2.87x +4.48,
95% confidence intervals: (0.47, 5.27), (3.27, 5.69)), (H) the cancers
except pancreatic, liver and esophagus cancers (r2=0.20, p=0.07,
equation: y=3.35x +4.36, 95% confidence intervals: (20.37, 7.07),
(2.85, 5.86)). Lung cancer is shown as an open triangle and
pancreatic, liver, esophagus cancers are shown as open circles.
Found at: doi:10.1371/journal.pone.0010031.s007 (0.04 MB
PDF)
Figure S7 FDA specific drug percentage values vs. lethality
values. FDA specific drug percentage values are plotted against
global lethality ratio for (A) 20 cancers (r2=0.01, p=0.71,
equation: y=0.37x +0.27, 95% confidence intervals: (21.66,
2.40), (0.12, 0.42)), (B) the cancers except lung cancer (r2=0.17,
p=0.08, equation: y=4.70x +0.14, 95% confidence intervals:
(20.55, 9.95), (20.06, 0.34)). FDA specific drug percentage values
are plotted against local lethality ratio for (C) 20 cancers (r2=0.14,
p=0.11, equation: y=20.34x +0.43, 95% confidence intervals:
(20.75, 0.08), (0.22, 0.64)), (D) the cancers except pancreatic, liver
and esophagus cancers (r2=0.00, p=0.86, equation: y=20.05x +
0.35, 95% confidence intervals: (20.66, 0.56), (0.11, 0.60)). Lung
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c a n c e r sa r es h o w na so p e nc i r c l e s .
Found at: doi:10.1371/journal.pone.0010031.s008 (0.04 MB
PDF)
Figure S8 Drug/mutation target-based cancer networks. (A)
Drug target-based cancer network, (B) Mutation target-based
cancer network.
Found at: doi:10.1371/journal.pone.0010031.s009 (0.38 MB
PDF)
Figure S9 Cluster dendogram of cancer types based on global
and local lethality values.
Found at: doi:10.1371/journal.pone.0010031.s010 (0.11 MB TIF)
Dataset S1 Drug and cancer-type association with a year tag,
based on FDA labels
Found at: doi:10.1371/journal.pone.0010031.s011 (0.04 MB
XLS)
Dataset S2 Phase 1, 2, and 3 clinical drug trials for cancer,
completed by 2009
Found at: doi:10.1371/journal.pone.0010031.s012 (0.39 MB
XLS)
Dataset S3 Drug and cancer-type association with a year tag of
start date, based on clinical trials
Found at: doi:10.1371/journal.pone.0010031.s013 (0.14 MB
XLS)
Dataset S4 Targets of FDA approved cancer drugs
Found at: doi:10.1371/journal.pone.0010031.s014 (0.04 MB
XLS)
Dataset S5 FDA drug targets of different cancer types
Found at: doi:10.1371/journal.pone.0010031.s015 (0.03 MB
XLS)
Dataset S6 Mutation targets of different cancer types
Found at: doi:10.1371/journal.pone.0010031.s016 (0.03 MB
XLS)
Table S1 Global and local lethality ratio values for different
cancers from 2001 to 2007
Found at: doi:10.1371/journal.pone.0010031.s017 (0.08 MB
DOC)
Table S2 Correlation values of weighted degree, approval
number values with global and local lethality values for 2001–2007
Found at: doi:10.1371/journal.pone.0010031.s018 (0.06 MB
DOC)
Table S3 Weight of the edges for the cancer networks based on
FDA approvals and clinical trials (Weights of cancer pairs with at
least one interaction in one of the two networks are given for both
FDA and clinical trial cancer networks.)
Found at: doi:10.1371/journal.pone.0010031.s019 (0.38 MB
DOC)
Table S4 Weighted degree values and p-values for FDA cancer
network from 2000 to 2007
Found at: doi:10.1371/journal.pone.0010031.s020 (0.11 MB
DOC)
Table S5 Clinical trial numbers along with distinct drug number
and specific drug number for clinical trials
Found at: doi:10.1371/journal.pone.0010031.s021 (0.05 MB
DOC)
Table S6 Cancer type pairs based on FDA drug targets, together
with weight of the edges
Found at: doi:10.1371/journal.pone.0010031.s022 (0.17 MB
DOC)
Table S7 Cancer type pairs based on mutation targets, together
with weight of the edges
Found at: doi:10.1371/journal.pone.0010031.s023 (0.11 MB
DOC)
Table S8 Comparison of mutation target-based and drug target-
based weight values of cancer pairs
Found at: doi:10.1371/journal.pone.0010031.s024 (0.21 MB
DOC)
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